arrow_back Back to App

Rx Price Reduction Act: Combating Unfair International Drug Pricing

This act aims to ensure Americans don't bear disproportionately high costs for new drug development. It establishes a new trade negotiator role to combat countries artificially lowering drug prices, protecting access to innovative therapies and potentially lowering costs for US patients.
Key points
Establishes a Chief Pharmaceutical Trade Negotiator to advocate for US pharmaceutical manufacturers and consumers.
Requires annual reports on high-income countries with unfair pharmaceutical trade practices, allowing for responsive actions.
Aims to ensure other countries pay their fair share for new drug development, potentially impacting drug availability and prices in the US.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_4376
Sponsor: Rep. Arrington, Jodey C. [R-TX-19]
Process start date: 2021-07-09
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

USTRx Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_4376.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-07-09.

What are the main provisions?

Key points include:

  • Establishes a Chief Pharmaceutical Trade Negotiator to advocate for US pharmaceutical manufacturers and consumers.
  • Requires annual reports on high-income countries with unfair pharmaceutical trade practices, allowing for responsive actions.
  • Aims to ensure other countries pay their fair share for new drug development, potentially impacting drug availability and prices in the US.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Arrington, Jodey C. [R-TX-19].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Trade.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Economy